News
March 1 (Reuters) - Endo International Plc said on Thursday it had obtained a preliminary injunction preventing privately-held QuVa Pharma Inc from marketing and releasing a compounded drug that ...
“We believe this will prove to be a substantial source of differentiation versus our competitors.” QuVa Pharma will leverage the resources and healthcare investment experience of Bain Capital ...
"We believe this will prove to be a substantial source of differentiation versus our competitors." QuVa Pharma will leverage the resources and healthcare investment experience of Bain Capital ...
QuVa was formed in August by Hinchen and Chief ... in the program will be viewed as having higher standards so that competition will weed out some of the bad players.
and other existing shareholders have provided $15 million in additional equity funding to QuVa Pharma Inc., a provider of sterile compounding pharmacy services. QuVa Pharma in a news release said ...
We believe this will be a significant advantage relative to our competitors.” QuVa Pharma will continue to leverage the healthcare investment experience and deep resources of Bain Capital Private ...
QuVa Pharma Inc. announced Thursday that it ... We believe this will be a significant advantage relative to our competitors.” ...
QuVa Pharma, a provider of essential medications in ready-to-administer injectable formats to hospitals, has secured a $275 million senior debt facility. Goldman Sachs was the lead backer with ...
We believe this will be a significant advantage relative to our competitors,” added Peter Jenkins, QuVa Pharma co-founder and chief development officer. QuVa Pharma received a majority equity ...
SUGAR LAND, Texas, Sept. 26, 2018 /PRNewswire/ -- QuVa Pharma, Inc. today announced it has commenced manufacturing in newly completed Suites 4 & 5 at its facility in Bloomsbury, New Jersey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback